ArticleRare tumors2019
Giant cell tumor of bone: Unusual features of a rare tumor.
Article in Rare tumors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Optimal management of giant cell tumor in the tibial plateau: A case report on curettage and cement reinforcement.Radiology case reports · 2026Article
- Recurrent Giant Cell Tumor of the Carpal Bones in an Adult Male Managed by En-bloc Excision, Extended Curettage, Bone Grafting, and all-Kirschner Wire Fixation: A Rare Case Report and Literature Review.Journal of orthopaedic case reports · 2025Article
- JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.Cancer medicine · 2025Observational
- Case Series: Outcome of Giant Cell Tumor in Small Bones of the Foot.Journal of orthopaedic case reports · 2025Article
- Molecular pathological insights into tumorigenesis and progression of giant cell tumor of bone.Journal of bone oncology · 2025Review
- Rare features of giant cell tumors of the bone: A case report.Experimental and therapeutic medicine · 2024Article
- Management of Giant Cell Tumor of Distal Radius-Does Curettage Work?Indian journal of surgical oncology · 2024Article
- Excision of a Giant Cell Tumor With Bone Grafting and Bone Cementing of the Proximal Humerus: A Case Report.Cureus · 2024Article
- Review
- Article
- MiR-217 regulates autophagy through OPG/RANKL/RANK in giant cell tumors.Journal of orthopaedic surgery and research · 2023Article
- Diagnostic value ofJournal of bone oncology · 2023Article
- Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.Current oncology (Toronto, Ont.) · 2022Article
- Secondary Malignancy in Giant Cell Tumor: A Single-Center Study.Current oncology (Toronto, Ont.) · 2022Review
- 3D-printed personalised prostheses for bone defect repair and reconstruction following resection of metacarpal giant cell tumours.Annals of translational medicine · 2021Article
- Visualization of hidden soft-tissue recurrence of giant cell tumor of bone enabled by preoperative denosumab treatment: a case description.Quantitative imaging in medicine and surgery · 2021Article
- Giant cell tumor of the sacrum.Proceedings (Baylor University. Medical Center) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor of bone is a benign tumor with an aggressive behavior. Its typical subarticular location and high recurrence risk can be associated with significant morbidity. Although benign, it can rarely metastasize especially to the lungs. Also, it can be multicentric in less than 1% of patients. Late malignant transformation, although rare, can occur with a very poor prognosis. This series reports on these unusual and challenging features and management considerations of giant cell tumor of bone. This retrospective study included review of the medical records of patients with a confirmed histopathological diagnosis of giant cell tumor of bone. A total of 25 patients (16 females and 9 males) with a mean age of 34.5 years were included; 22 had primary tumors, while 3 were referred with recurrent tumors. Pain was the most common presenting symptom. Most patients had grade III tumors. Tumors around the knee were the most common. Multicentric tumors were detected in three patients. Twenty-three patients (20 primary giant cell tumor of bone and 3 with recurrence) received treatment. Most patients (15/23) were treated with intralesional curettage with or without adjuvants. Seven patients had wide excision. Recurrence was seen in 45% (9/20) of primary giant cell tumor of bone especially with difficult anatomical locations. Most recurrences occurred more than 4 years after treatment. Pulmonary nodules were detected in four patients; two of them showed resolution during follow-up. One patient developed secondary sarcoma transformation with a fatal outcome. Giant cell tumor of bone was more common in females. Long bones were more affected, especially around the knee. Intralesional curettage was the most frequently used treatment. Recurrence was associated with inadequate tumor resection (especially in difficult anatomical location), younger age, male gender, and advanced local tumor grade. Denosumab can be used in the treatment of pulmonary metastasis, multicentric and recurrent giant cell tumor of bone. Due to late recurrence and malignant transformation, a prolonged follow-up is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.